

Freedom of Information Request: Our Reference CTHB_343_18

You asked:

1. How many asthma patients aged 18 and over have been treated in the past 3 months [latest 3 months available],
2. How many paediatric asthma treated patients [aged 6-17] have been treated?
3. How many severe asthmatic patients [BTS guidelines, step 4 or 5] have been treated?
4. How many severe allergic asthma patients [severe persistent confirmed allergic IgE-mediated asthma OR severe persistent confirmed allergic eosinophilic asthma
Severe asthma patients treated with:
 - Omalizumab [Xolair]
 - Mepolizumab [Nucala]
 - Reslizumab [Cinqaero]
 - Benralizumab [Fasenra]
 - Other [Please state]
5. How many paediatric severe asthma patients have been treated with Xolair/omalizumab in the past 3 months?
6. How many chronic spontaneous urticaria (CSU) patients have been treated with Xolair/omalizumab in the past 3 months?

Our response:

In response to your recent query outlined above please find below where possible the information you have requested. Explanations have been provided where we are unable to provide the data requested.

Adult Patients (past 3 months)		
Medicine	Condition	Number of Patients
Omalizumab [Xolair]	Severe persistent allergic asthma	25
Mepolizumab [Nucala]	Severe refractory eosinophilic asthma	14
Reslizumab [Cinqaero]	Severe eosinophilic asthma	Not in use – Clinician Decision.
Benralizumab [Fasenra]	Severe asthma	Not in use: Benralizumab has not yet been appraised or recommended by NICE/AWMSG. NICE are currently in the process of appraising benralizumab. Anticipated

		publication due date Dec 18.
Omalizumab [Xolair]	Previously treated chronic spontaneous urticaria	**

** patient numbers are less than 5, therefore figures have been withheld due to the low numbers involved.

We are unable to provide you with the level of detail you are seeking as to the treatment undertaken by this patient as there is a potential risk of identifying the individual if this was disclosed. Therefore, the data is classed as personal data as defined under the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute as unfair and unlawful processing **in regard to** Articles 5, 6, and 9 of GDPR. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This exemption is absolute and therefore there is no requirement to apply the public interest test.